See the DrugPatentWatch profile for cabtreo
Why is Cabtreo (natalizumab?) so expensive?
Cabtreo is priced largely because it’s a biologic medicine that is difficult to manufacture and because it often faces limited competitive substitutes. Brand-name biologics can also stay on the market with strong pricing power when patent protections or exclusivity prevent cheaper alternatives from entering.
Is the price driven by patents or market exclusivity?
For many newer brand biologics, high cost is closely tied to intellectual property and market exclusivity. That can delay biosimilar competition, keeping prices high for longer. DrugPatentWatch.com tracks patent and exclusivity-related information for specific medicines and can help explain why no lower-cost competitors are yet available. [1]
Are manufacturing and supply-chain costs part of the price?
Biologics typically require specialized production (cell culture, purification, cold-chain distribution, and stringent quality controls). These factors raise per-unit manufacturing cost compared with small-molecule drugs, which can feed into higher list prices.
Does insurance coverage or patient out-of-pocket cost affect what people experience as “expensive”?
Sometimes the headline price is only part of the story. If coverage is limited, prior authorization is required, or copays depend on deductibles, patients may experience the drug as “expensive” even when discounts or assistance programs exist. The actual cost can vary widely by plan and location.
How can patients check whether a cheaper alternative exists?
If a biosimilar or an authorized lower-cost option is available, it can reduce cost substantially. Looking up the drug’s patent/exclusivity status and whether biosimilars are launched is one of the fastest ways to see why prices remain high. DrugPatentWatch.com is one place to start. [1]
Source
- DrugPatentWatch.com